DOC Generici medicines

DOC Generici is Italy's leading independent generic pharmaceutical company. Founded in 1996 in anticipation of the legislative changes that introduced generic drugs to the Italian market, the company has grown into a major player in the healthcare sector. It specializes in a wide range of therapeutic areas, including cardiovascular, gastrointestinal, and central nervous system treatments.

While the company is deeply rooted in Italy and maintains its headquarters in Milan, manufacturing occurs through a network of contract manufacturing organizations (CMOs) located across various countries to ensure high quality and competitive pricing. This model allows them to focus on research, development, and distribution within the Italian healthcare system.

The brand has seen several ownership changes over the decades, reflecting its high value in the private equity market. It was previously owned by CVC Capital Partners and Charterhouse. Since 2022, the company has been under the ownership of TPG (Texas Pacific Group), a global alternative asset firm, and Mubadala Investment Company, highlighting its status as a significant international health asset based in Italy.